MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules.
Targeting cellular mitosis is an attractive antitumor strategy. Here, we reported MT7, a novel compound from the 6H-Pyrido[2',1':2,3]imidazo [4,5-c]isoquinolin- 5(6H)-one library generated by using the multi-component reaction strategy, as a new mitotic inhibitor. MT7 elicited apparent inhibition of cell proliferation by arresting mitosis specifically and reversibly in various tumor cell lines originating from different human tissues. Detailed mechanistic studies revealed that MT7 induced typical gene expression profiles related to mitotic arrest shown by cDNA microarray assays. Connectivity Map was used to analyze the microarray data and suggested that MT7 was possibly a tubulin inhibitor due to its similar gene expression profiles to those of the known tubulin inhibitors demecolcine, celastrol and paclitaxel. Further analyses demonstrated that MT7 inhibited the polymerization of cellular microtubules although it was not detectable to bind to purified tubulin. The inhibition of cellular tubulin polymerization by MT7 subsequently resulted in the disruption of mitotic spindle formation, activated the spindle assembly checkpoint and consequently arrested the cells at mitosis. The persistent mitotic arrest by the treatment with MT7 led the tested tumor cells to apoptosis. Our data indicate that MT7 could act as a promising lead for further optimization, in hopes of developing new anticancer therapeutics and being used to probe the biology of mitosis, specifically, the mode of interference with microtubules.
Zhang
Zhixiang
Z
Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People's Republic of China.
Meng
Tao
T
He
Jingxue
J
Li
Ming
M
Tong
Lin-Jiang
LJ
Xiong
Bing
B
Lin
Liping
L
Shen
Jingkang
J
Miao
Ze-Hong
ZH
Ding
Jian
J
D050256:Antimitotic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D020650:Combinatorial Chemistry Techniques; D004354:Drug Screening Assays, Antitumor; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D052138:Genes, Neoplasm / Q000235:genetics; D006576:Heterocyclic Compounds, 4 or More Rings / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008870:Microtubules / Q000187:drug effects* / Q000378:metabolism*; D008938:Mitosis / Q000187:drug effects*; D054852:Small Molecule Libraries / Q000737:chemistry / Q000494:pharmacology*; D008941:Spindle Apparatus / Q000187:drug effects / Q000378:metabolism; D014404:Tubulin / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
C555519:6-(4-methoxybenzyl)pyrido(2',1'-2,3)imidazo(4,5-c)isoquinolin-5(6H)-one; D050256:Antimitotic Agents; D006576:Heterocyclic Compounds, 4 or More Rings; D054852:Small Molecule Libraries; D014404:Tubulin
Nat Biotechnol. 2005 Mar;23(3):377-83
15765094
Nat Rev Cancer. 2007 Jan;7(1):54-60
17186018
Clin Cancer Res. 2006 Jul 1;12(13):4080-9
16818708
Plant Cell Physiol. 2007 Dec;48(12):1764-74
17967797
Clin Cancer Res. 2007 Feb 15;13(4):1298-307
17287296
Nat Rev Cancer. 2007 Feb;7(2):107-17
17251917
Nature. 2006 Nov 16;444(7117):337-42
17086191
Cancer Cell. 2007 Jun;11(6):555-69
17560336
Nat Rev Cancer. 2004 Apr;4(4):253-65
15057285
Science. 1999 Oct 29;286(5441):971-4
10542155
EMBO J. 2002 Dec 16;21(24):6820-31
12486003
J Med Chem. 1976 Nov;19(11):1352-4
1003417
Plant Cell. 2003 Nov;15(11):2666-79
14508002
Mol Cell. 2004 May 7;14(3):375-85
15125840
Mol Cell Biol. 1997 Oct;17(10):5791-802
9315637
Curr Opin Pharmacol. 2001 Aug;1(4):370-7
11710735
Cancer Res. 1991 Sep 15;51(18):4903-8
1654204
Oncogene. 2004 Apr 12;23(16):2825-37
15077146
Methods Mol Biol. 2004;281:213-25
15220532
Chem Biol. 2004 Jan;11(1):135-46
15113003
Mol Cancer Ther. 2006 Dec;5(12):2963-9
17172401
Biochemistry. 1981 May 26;20(11):3247-52
6113842
J Cell Biol. 2003 Apr 28;161(2):267-80
12719470
Mol Biol Cell. 2006 Mar;17(3):1041-50
16371510
J Cell Biol. 1993 Feb;120(3):613-24
8381119
Nat Cell Biol. 1999 Jun;1(2):82-7
10559878
Proc Natl Acad Sci U S A. 1973 Mar;70(3):765-8
4514990
Nat Rev Cancer. 2004 Dec;4(12):927-36
15573114
Dev Cell. 2004 Nov;7(5):637-51
15525526
Nat Genet. 2003 Jul;34(3):267-73
12808457
Pharmazie. 1999 Dec;54(12):876-8
10631751
Trends Biochem Sci. 1997 Jun;22(6):197-202
9204705
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
16199517
Mol Biol Cell. 2002 Jun;13(6):1977-2000
12058064
Clin Cancer Res. 2007 May 15;13(10):2849-54
17504982
J Cell Biol. 2000 Jul 10;150(1):13-26
10893252
J Comb Chem. 2007 Sep-Oct;9(5):739-41
17602597
Cancer Cell. 2005 Jul;8(1):49-59
16023598
Biochem Pharmacol. 2001 Sep 15;62(6):733-41
11551518
Mol Cancer Ther. 2007 Sep;6(9):2429-40
17876042
J Cell Sci. 2001 Jul;114(Pt 13):2357-8
11559744
Cell. 1980 May;20(1):29-36
7388944
J Biol Chem. 2001 May 11;276(19):16146-54
11278715
Biochemistry. 1992 Dec 8;31(48):12069-75
1333791
Mol Cell. 1998 Jul;2(1):65-73
9702192
FEBS Lett. 1979 Mar 15;99(2):333-6
428557
Cell Motil Cytoskeleton. 2005 Jul;61(3):145-60
15887295
Bioorg Med Chem Lett. 2008 Feb 1;18(3):1050-2
18164197
EMBO J. 2003 Mar 3;22(5):1168-79
12606581
EMBO J. 1992 Mar;11(3):961-71
1312467
Nat Rev Cancer. 2005 Jan;5(1):42-50
15630414
Science. 1996 Dec 6;274(5293):1672-7
8939849
J Med Chem. 2004 Oct 7;47(21):5126-39
15456256
Science. 2006 Sep 29;313(5795):1929-35
17008526